Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Bioactive Components for Depression: Naringin, Caffeine, Probiotics, Saffron and Lavender May Exert Antidepressant Effects Through Inflammation Modulation Publisher



Shamabadi A1, 2 ; Akhondzadeh S2
Authors

Source: Journal of Iranian Medical Council Published:2022


Abstract

[No abstract available]
Related Docs
View other Related Docs
1. Efficacy and Tolerability of Lavandula Angustifolia in Treating Patients With the Diagnosis of Depression: A Systematic Review of Randomized Controlled Trials, Journal of Complementary and Integrative Medicine (2023)
2. Adjuvant Palmitoylethanolamide Therapy With Risperidone Improves Negative Symptoms in Patients With Schizophrenia: A Randomized, Double-Blinded, Placebo-Controlled Trial, Psychiatry Research (2022)
3. The Inflammatory Mechanism in Depression and Some Possible Effective Agents, Journal of Iranian Medical Council (2022)
Experts (# of related papers)
Shahin Akhondzadeh Basti (8)
Mahtab Motamed (1)
Other Related Docs
4. Advances in Alternative and Integrative Medicine in the Treatment of Depression: A Review of the Evidence, Archives of Iranian Medicine (2021)
5. Crocin Administration From Childhood to Adulthood Increases Hippocampal Neurogenesis and Synaptogenesis in Male Mice, Journal of Kerman University of Medical Sciences (2021)
6. Efficacy and Safety of Palmitoylethanolamide As an Adjunctive Treatment for Acute Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Psychiatry and Clinical Neurosciences (2022)
7. Evidence for Anti-Inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial, Clinical Neuropharmacology (2022)
8. Risperidone Combination Therapy With Adalimumab for Treatment of Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2022)
9. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)